Diagnosis and treatment of polycystic ovary syndrome: an endocrine society clinical practice guideline

Authors

  • Richard S. Legro Penn State University College of Medicine, Hershey, Pennsylvania, United States
  • Silva A. Arslanian Children’s Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania David A. Ehrmann, University of Chicago, Chicago, United States
  • David A. Ehrmann University of Chicago, Chicago, Illinois, United States
  • Kathleen M. Hoeger University of Rochester Medical Center, Rochester, New York, United States
  • M. Hassan Murad Mayo Clinic, Rochester, Minnesota, United States
  • Renato Pasquali Orsola-Malpighi Hospital, University Alma Mater Studiorum, Bologna, Italy, Italy
  • Corrine K. Welt Massachusetts General Hospital, Boston, United States

DOI:

https://doi.org/10.18370/2309-4117.2014.20.22-35

Keywords:

polycystic ovary syndrome, ovulatory dysfunction, hirsutism, acne, infertility, Clinical Guideline, Endocrine Society

Abstract

Objective: The aim was to formulate practice guidelines for the diagnosis and treatment of polycystic ovary syndrome (PCO S).

Participants: An Endocrine Society-appointed Task Force of experts, a methodologist, and a medical writer developed the guideline.

Evidence: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE ) system to describe both the strength of recommendations and the quality of evidence.

Consensus Process: Committees and members of The Endocrine Society and the European Society of Endocrinology reviewed and commented on preliminary drafts of these guidelines. Two systematic reviews were conducted to summarize supporting evidence.

Conclusions: We suggest using the Rotterdam criteria for diagnosing PCO S (presence of two of the following criteria: androgen excess, ovulatory dysfunction, or polycystic ovaries). Establishing a diagnosis of PCO S is problematic in adolescents and menopausal women. Hyperandrogenism is central to the presentation in adolescents, whereas there is no consistent phenotype in postmenopausal women. Evaluation of women with PCO S should exclude alternate androgen-excess disorders and risk factors for endometrial cancer, mood disorders, obstructive sleep apnea, diabetes, and cardiovascular disease. Hormonal contraceptives are the first-line management for menstrual abnormalities and hirsutism/acne in PCO S. Clomiphene is currently the first-line therapy for infertility; metformin is beneficial for metabolic/glycemic abnormalities and for improving menstrual irregularities, but it has limited or no benefit in treating hirsutism, acne, or infertility. Hormonal contraceptives and metformin are the treatment options in adolescents with PCO S. The role of weight loss in improving PCO S status per se is uncertain, but lifestyle intervention is beneficial in overweight/obese patients for other health benefits. Thiazolidinediones have an unfavorable risk benefit ratio overall, and statins require further study.

References

  1. 1. Martin, K.A., Chang, R.J., Ehrmann, D.A., et al. “Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society clinical practice guideline.” J Clin Endocrinol Metab., 93(2008):1105-1120.
  2. 2. Rosenzweig, J.L., Ferrannini, E., Grundy, S.M., et al. “Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an Endocrine Society clinical practice guideline.” J Clin Endocrinol Metab., 93(2008):3671-3689.
  3. 3. Centers for Disease Control and Prevention. “US medical eligibility criteria for contraceptive use.” MMWR Recomm Rep., 59(2010):1-86.
  4. 4. Atkins, D., Best, D., Briss, P.A., et al. “Grading quality of evidence and strength of recommendations.” BMJ, 328(2004):1490.
  5. 5. Swiglo, B.A., Murad, M.H., Schünemann, H.J., et al. “A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system.” J Clin Endocrinol Metab., 93(2008):666-673.
  6. 6. Zawadzki, J., Dunaif, A. “Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A., Givens J., Haseltine F., Haseltine G., eds. Polycystic Ovary Syndrome.” 1st ed. Oxford, England: Blackwell Scientific (1992):377-384.
  7. 7. Rotterdam ESHRE/ASRM-Sponsored PCO S Consensus Workshop Group. “Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCO S).” Hum Reprod., 19(2004):41-47.
  8. 8. Thessaloniki ESHRE/ASRM-Sponsored PCO S Consensus Workshop Group. “Consensus on infertility treatment related to polycystic ovary syndrome.” Hum Reprod., 23(2008):462-477.
  9. 9. Azziz, R., Carmina, E., Dewailly, D., et al; Task Force on the Phenotype of the Polycystic Ovary Syndrome of the Androgen Excess andPCO S Society. “The Androgen Excess and PCO S Society criteria for the polycystic ovary syndrome: the complete task force report.” Fertil Steril, 91(2009):456-488.
  10. 10. Ladenson, P.W., Singer, P.A., Ain, K.B., et al. “American Thyroid Association guidelines for detection of thyroid dysfunction.” Arch Intern Med., 160(2000):1573-1575.
  11. 11. Melmed, S., Casanueva, F.F., Hoffman, A.R., et al; Endocrine Society. “Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline.” J Clin Endocrinol Metab., 96(2011): 273–288.
  12. 12. Speiser, P.W., Azziz, R., Baskin, L.S., et al; Endocrine Society. «Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline.» J Clin Endocrinol Metab., 95(2010):4133-4160.
  13. 13. Vermeulen, A., Ando, S. “Prolactin and adrenal androgen secretion.” Clin Endocrinol (Oxf), 8(1978):295-303.
  14. 14. Glasow, A., Breidert, M., Haidan, A., Anderegg, U., Kelly, P.A., Bornstein, S.R. “Functional aspects of the effect of prolactin (PRL) on adrenal steroidogenesis and distribution of the PRL receptor in the human adrenal gland.” J Clin Endocrinol Metab., 81(1996):3103-3111.
  15. 15. Azziz, R., Sanchez, L.A., Knochenhauer, E.S., et al. “Androgen excess in women: experience with over 1000 consecutive patients.” J Clin Endocrinol Metab., 89(2004):453-462.
  16. 16. Carmina, E., Rosato, F., Jannì, A., Rizzo, M., Longo, R.A. “Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 womenreferred because of clinical hyperandrogenism.” J Clin Endocrinol Metab.,
  17. (2006):2-6.
  18. 17. Morse, C.B., Sammel, M.D., Shaunik, A., et al. “Performance of human chorionic gonadotropin curves in women at risk for ectopic pregnancy: exceptions to the rules.” Fertil Steril, 97(2012):101-106.
  19. 18. Wang, J.G., Lobo, R.A. “The complex relationship between hypothalamic amenorrhea and polycystic ovary syndrome.” J
  20. Clin Endocrinol Metab., 93(2008):1394-1397.
  21. 19. Nieman, L.K., Biller, B.M., Findling, J.W., et al. “The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline.” J Clin Endocrinol Metab., 93(2008):1526-1540.
  22. 20. Melmed, S., Colao, A., Barkan A., et al; Acromegaly Consensus Group. “Guidelines for acromegaly management: an update.” J Clin Endocrinol Metab., 94(2009):1509-1517.
  23. 21. Apter, D. “Endocrine and metabolic abnormalities in adolescents with a PCO S-like condition: consequences
  24. for adult reproduction.” Trends Endocrinol Metab., 9(1998):58-61.
  25. 22. Rosenfield, R.L., Ghai, K., Ehrmann, D.A., Barnes, R.B. “Diagnosis of the polycystic ovary syndrome in adolescence: comparison of adolescent and adult hyperandrogenism.” J Pediatr Endocrinol Meta., 13(suppl 5) (2000):1285-1289.
  26. 23. Homburg, R., Lambalk, C.B. “Polycystic ovary syndrome in adolescence – a therapeutic conundrum.” Hum Reprod.,
  27. (2004):1039-1042.
  28. 24. Olutunmbi, Y., Paley, K., English, J.C., 3rd. ”Adolescent female acne: etiology and management.” J Pediatr Adolesc Gynecol., 21(2008): 171- 176. doi: 10.1210/jc.2013-2350 jcem.endojournals.org 21.
  29. 25. Carmina, E., Oberfield, S.E., Lobo, R.A. “The diagnosis of polycystic ovary syndrome in adolescents.” Am J Obstet Gynecol., 203(2010): 201.e1-e5.
  30. 26. Lucky, A.W., Biro, F.M., Daniels, S.R., Cedars, M.I., Khoury, P.R., Morrison, J.A. “The prevalence of upper lip hair in black and white girls during puberty: a new standard.” J Pediatr., 138(2001):134-136.
  31. 27. Pfeifer, S.M., Kives, S. “Polycystic ovary syndrome in the adolescent.” Obstet Gynecol Clin North Am., 36(2009):129-152.
  32. 28. Bekx, M.T., Connor, E.C., Allen, D.B. “Characteristics of adolescents presenting to a multidisciplinary clinic for polycystic ovarian syndrome.” J Pediatr Adolesc Gynecol., 23(2010):7-10.
  33. 29. Diamanti-Kandarakis, E. “PCO S in adolescents.” Best Pract Res Clin Obstet Gynaecol., 24(2010):173-183.
  34. 30. Warren-Ulanch, J., Arslanian, S. “Treatment of PCO S in adolescence.” Best Pract Res Clin Endocrinol Metab., 20(2006):311-330.
  35. 31. Rosner, W., Auchus, R.J., Azziz, R., Sluss, P.M., Raff, H. “Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement.” J Clin Endocrinol Metab., 92(2007):405-413.
  36. 32. McCartney, C.R., Blank, S.K., Prendergast, K.A., et al. “Obesity and sex steroid changes across puberty: evidence for marked hyperandrogenemia in preand early pubertal obese girls.” J Clin Endocrinol Metab., 92(2007):430-436.
  37. 33. Apter, D., Vihko, R. “Endocrine determinants of fertility: serum androgen concentrations during follow-up of adolescents into the third decade of life.” J Clin Endocrinol Metab., 71(1990):970-974.
  38. 34. Shayya, R., Chang, R.J. “Reproductive endocrinology of adolescent polycystic ovary syndrome.” BJOG., 117(2010):150-155.
  39. 35. Bridges, N.A., Cooke, A., Healy, M.J., Hindmarsh, P.C., Brook, C.G. “Standards for ovarian volume in childhood and puberty.” Fertil Steril., 60(1993):456-460.
  40. 36. Pawelczak, M., Kenigsberg, L., Milla, S., Liu, Y.H., Shah, B. “Elevated serum anti-Müllerian hormone in adolescents with polycystic ovary syndrome: relationship to ultrasound features.” J Pediatr Endocrinol Metab., 25(2012):983-989.
  41. 37. Rosenfield, R.L., Wroblewski, K., Padmanabhan, V., Littlejohn, E., Mortensen, M., Ehrmann, D.A. “Antimüllerian hormone levels are independently related to ovarian hyperandrogenism and polycystic ovaries.” Fertil Steril., 98(2012):242-249.
  42. 38. Johnstone, E.B., Rosen, M.P., Neril, R., et al. “The polycystic ovary post-Rotterdam: a common, age-dependent finding in ovulatory women without metabolic significance.” J Clin Endocrinol Metab., 95(2010):4965-4972.
  43. 39. Alsamarai, S., Adams, J.M., Murphy, M.K., et al. “Criteria for polycystic ovarian morphology in polycystic ovary syndrome as a function of age.” J Clin Endocrinol Metab., 94(2009):4961-4970.
  44. 40. Pigny, P., Merlen, E., Robert, Y., et al. “Elevated serum level of antimullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest.” J Clin Endocrinol Metab., 88(2003):5957-5962.
  45. 41. Mulders, A.G., Laven, J.S., Eijkemans, M.J., de Jong, F.H., Themmen, A.P., Fauser, B.C. “Changes in anti-Müllerian hormone serum concentrations over time suggest delayed ovarian ageing in normogonadotrophic anovulatory infertility.” Hum Reprod., 19(2004):2036-2042.
  46. 42. Piltonen, T., Morin-Papunen, L., Koivunen, R., Perheentupa, A., Ruokonen, A., Tapanainen, J.S. “Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome.” Hum Reprod., 20(2005):1820-1826.
  47. 43. Azziz, R., Carmina, E., Dewailly, D., et al. “Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline.” J Clin Endocrinol Metab., 91(2006):4237-4245.
  48. 44. Davison, S.L., Bell, R., Donath, S., Montalto, J.G., Davis, S.R. “Androgen levels in adult females: changes with age, menopause, and oophorectomy.” J Clin Endocrinol Metab., 90(2005):3847-3853.
  49. 45. Winters, S.J., Talbott, E., Guzick, D.S., Zborowski, J., McHugh, K.P. “Serum testosterone levels decrease in middle age in women with the polycystic ovary syndrome.” Fertil Steril., 73(2000):724-729.
  50. 46. Elting, M.W., Korsen, T.J., Rekers-Mombarg, L.T., Schoemaker, J. “Women with polycystic ovary syndrome gain regular menstrual cycles when ageing.” Hum Reprod., 15(2000):24-28.
  51. 47. Elting, M.W., Kwee, J., Korsen, T.J., Rekers-Mombarg, L.T., Schoemaker, J. “Aging women with polycystic ovary syndrome who achieve regular menstrual cycles have a smaller follicle cohort than those who continue to have irregular cycles.” Fertil Steril., 79(2003):1154-1160.
  52. 48. Legro, R.S., Schlaff, W.D., Diamond, M.P., et al; Reproductive Medicine Network. “Total testosterone assays in women with polycystic ovary syndrome: precision and correlation with hirsutism.” J Clin Endocrinol Metab., 95(2010):5305-5313.
  53. 49. Sam, S., Legro, R.S., Essah, P.A., Apridonidze, T., Dunaif, A. “Evidence for metabolic and reproductive phenotypes in mothers of women with polycystic ovary syndrome.” Proc Natl Acad Sci USA., 103(2006):7030-7035.
  54. 50. Semple, R.K., Savage, D.B., Halsall, D.J., O’Rahilly, S. “Syndromes of severe insulin resistance and/or lipodystrophy.” In: Weiss R.E., Refetoff S., eds. Genetic Diagnosis of Endocrine Diseases. London, UK: Academic Press, Elsevier, Inc. (2010):105-115.
  55. 51. Sari, R., Akman, A., Alpsoy, E., Balci, M.K. “The metabolic profile in patients with skin tags.” Clin Exp Med., 10(2010):193-197.
  56. 52. Azziz, R., Woods, K.S., Reyna, R., Key, T.J., Knochenhauer, E.S., Yildiz, B.O. “The prevalence and features of the polycystic ovary syndrome in an unselected population.” J Clin Endocrinol Metab., 89(2004):2745-2749.
  57. 53. Ozdemir, S., Ozdemir, M., Görkemli, H., Kiyici, A., Bodur, S. “Specific dermatologic features of the polycystic ovary syndrome and its association with biochemical markers of the metabolic syndrome and hyperandrogenism.” Acta Obstet Gynecol Scand., 89(2010):199-204.
  58. 54. Rausch, M.E., Legro, R.S., Barnhart, H.X., et al; for the Cooperative Multicenter Reproductive Medicine Network. “Predictors of pregnancy in women with polycystic ovary syndrome.” J Clin Endocrinol Metab., 94(2009):3458-3466.
  59. 55. Hatch, R., Rosenfield, R.L., Kim, M.H., Tredway, D. «Hirsutism: implications, etiology, and management.» Am J Obstet Gynecol., 140(1981):815-830.
  60. 56. Lowenstein, E.J. “Diagnosis and management of the dermatologic manifestations of the polycystic ovary syndrome.” Dermatol Ther., 19(2006):210-223.
  61. 57. Deplewski, D., Rosenfield, R.L. “Role of hormones in pilosebaceous unit development.” Endocr Rev., 21(2000):363-392.
  62. 58. Ludwig, E. “Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex.” Br J Dermatol., 97(1977):247-254.
  63. 59. Arias-Santiago, S., Gutiérrez-Salmerón, M.T., Castellote-Caballero, L., Buendía-Eisman, A., Naranjo-Sintes, R. “Androgenetic alopecia and cardiovascular risk factors in men and women: a comparative study.” J Am Acad Dermatol., 63(2010):420-429.
  64. 60. Matilainen, V., Laakso, M., Hirsso, P., Koskela, P., Rajala, U., Keinänen-Kiukaanniemi, S. “Hair loss, insulin resistance, and heredity in middle-aged women.” A population-based study. Lancet., 356(2000):1165-1166.
  65. 61. Ekmekci, T.R., Ucak, S., Basat, O., Koslu, A., Altuntas, Y. “The presence of insulin resistance and comparison of various insulin sensivity indices in women with androgenetic alopecia.” J Cardiovasc Risk., 10(2003):227-231.
  66. 62. Karrer-Voegeli, S., Rey, F., Reymond, M.J., Meuwly, J.Y., Gaillard, R.C., Gomez, F. “Androgen dependence of hirsutism, acne, and alopecia in women: retrospective analysis of 228 patients investigated for hyperandrogenism.” Medicine (Baltimore)., 88(2009):32-45.
  67. 63. Stein, I.F., Leventhal, M.L. “Amenorrhea associated with bilateral polycystic ovaries.” Am J Obstet Gynecol., 29(1935):181-191.
  68. 64. Goldzieher, J.W., Axelrod, L.R. “Clinical and biochemical features of polycystic ovarian disease.” Fertil Steril., 14(1963):631-653.
  69. 65. Balen, A.H. Conway, G.S. Kaltsas, G. et al. “Polycystic ovary syndrome:22 Legro et al Guidelines on PCO S J Clin Endocrinol Metab the spectrum of the disorder in 1741 patients.” Hum Reprod., 10(1995):2107-2111.
  70. 66. Bhattacharya, S., Porter, M., Amalraj, E., et al. “The epidemiology of infertility in the North East of Scotland.” Hum Reprod., 24(2009):3096-3107.
  71. 67. Hull, M.G. “Epidemiology of infertility and polycystic ovarian disease:endocrinological and demographic studies.” Gynecol Endocrinol., 1(1987):235-245.
  72. 68. Imani, B., Eijkemans, M.J., te Velde, E.R., Habbema, J.D., Fauser, B.C. “Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility.” J Clin Endocrinol Metab., 83(1998):2361-2365.
  73. 69. Azziz, R., Ehrmann, D., Legro, R.S., et al. “Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial.” J Clin Endocrinol Metab., 86(2001):1626-1632.
  74. 70. Hudecova, M., Holte, J., Olovsson, M., Sundström Poromaa, I. “Longterm follow-up of patients with polycystic ovary syndrome: reproductive outcome and ovarian reserve.” Hum Reprod., 24(2009):1176-1183.
  75. 71. Trounson, A., Wood, C., Kausche, A. “In vitro maturation and the fertilization and developmental competence of oocytes recovered from untreated polycystic ovarian patients.” Fertil Steril., 62(1994):353-362.
  76. 72. Wood, J.R., Dumesic, D.A., Abbott, D.H., Strauss, J.F., 3rd. “Molecular abnormalities in oocytes from women with polycystic ovary syndrome revealed by microarray analysis.” J Clin Endocrinol Metab., 92(2007):705-713.
  77. 73. Apparao, K.B., Lovely, L.P., Gui, Y., Lininger, R.A., Lessey, B.A. “Elevated endometrial androgen receptor expression in women with polycystic ovarian syndrome.” Biol Reprod., 66(2002):297-304.
  78. 74. Gregory, C.W., Wilson, E.M., Apparao, K.B., et al. “Steroid receptor coactivator expression throughout the menstrual cycle in normal and abnormal endometrium.” J Clin Endocrinol Metab., 87(2002):2960-2966.
  79. 75. Bolúmar, F., Olsen, J., Rebagliato, M., Sáez-Lloret, I., Bisanti, L. “Body mass index and delayed conception: a European multicenter study on infertility and subfecundity.” Am J Epidemiol., 151(2000):1072-1079.
  80. 76. Legro, R.S., Barnhart, H.X., Schlaff, W.D., et al. “Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.” N Engl J Med., 356(2007):551-566.
  81. 77. Homburg, R., Berkowitz, D., Levy, T., Feldberg, D., Ashkenazi, J., Ben-Rafael, Z. “In vitro fertilization and embryo transfer for the treatment of infertility associated with polycystic ovary syndrome.” Fertil Steril., 60(1993):858-863.
  82. 78. Balen, A.H., Laven, J.S., Tan, S.L., Dewailly, D. “Ultrasound assessment of the polycystic ovary: international consensus definitions.” Hum Reprod Update., 9(2003):505-514.
  83. 79. Heijnen, E.M., Eijkemans, M.J., Hughes, E.G., Laven, J.S., Macklon, N.S., Fauser, B.C. “A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome.” Hum Reprod Update., 12(2006):13-21.
  84. 80. Holte, J., Gennarelli, G., Wide, L., Lithell, H., Berne, C. “High prevalence of polycystic ovaries and associated clinical, endocrine, and metabolic features in women with previous gestational diabetes mellitus.” J Clin Endocrinol Metab., 83(1998):1143-1150.
  85. 81. Mikola, M., Hiilesmaa, V., Halttunen, M., Suhonen, L., Tiitinen, A. “Obstetric outcome in women with polycystic ovarian syndrome.” Hum Reprod., 16(2001):226-229.
  86. 82. Haakova, L., Cibula, D., Rezabek, K., Hill, M., Fanta, M., Zivny, J. “Pregnancy outcome inwomenwithPCO Sand in controls matched by age and weight.” Hum Reprod., 18(2003):1438-1441.
  87. 83. Boomsma, C.M., Eijkemans, M.J., Hughes, E.G., Visser, G.H., Fauser, B.C., Macklon, N.S. “A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome.» Hum Reprod Update., 12(2006):673-683.
  88. 84. Abbott, D.H., Zhou, R., Bird, I.M., Dumesic, D.A., Conley, A.J. «Fetal programming of adrenal androgen excess: lessons from a nonhuman primate model of polycystic ovary syndrome.” Endocr Dev., 13(2008):145-158.
  89. 85. Ortega, H.H., Rey, F., Velazquez, M.M., Padmanabhan, V. “Developmental programming: effect of prenatal steroid excess on intraovarian components of insulin signaling pathway and related proteins in sheep.” Biol Reprod., 82(2010):1065-1075.
  90. 86. Recabarren, S.E., Padmanabhan, V., Codner, E., et al. “Postnatal developmental consequences of altered insulin sensitivity in female sheep treated prenatally with testosterone.” Am J Physiol Endocrinol Metab., 289(2005):E801-E806.
  91. 87. Barnes, R.B., Rosenfield, R.L., Ehrmann, D.A., et al. “Ovarian hyperandrogynism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women.” J Clin Endocrinol Metab., 79(1994):1328-1333.
  92. 88. Ghizzoni, L. Virdis, R., Vottero, A., et al. “Pituitary-ovarian responses to leuprolide acetate testing in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.” J Clin Endocrinol Metab., 81(1996):601-606.
  93. 89. Sir-Petermann, T., Maliqueo, M., Angel, B., Lara, H.E., Pérez-Bravo, F., Recabarren, S.E. “Maternal serum androgens in pregnant women with polycystic ovarian syndrome: possible implications in prenatal androgenization.” Hum Reprod, 17(2002):2573-2579.
  94. 90. Hickey, M., Sloboda, D.M., Atkinson, H.C., et al. “The relationship between maternal and umbilical cord androgen levels and polycystic ovary syndrome in adolescence: a prospective cohort study.” J Clin Endocrinol Metab., 94(2009):3714-3720.
  95. 91. Godfrey, K.M., Barker, D.J. “Fetal nutrition and adult disease.” AmJ Clin Nutr., 71(5 suppl) (2000):1344S-1352S.
  96. 92. Sir-Petermann, T., Hitchsfeld, C., Maliqueo, M., et al. “Birth weight in offspring of mothers with polycystic ovarian syndrome.” Hum Reprod., 20(2005):2122-2126.
  97. 93. Ibáñez, L., Potau, N., Ferrer, A., Rodriguez-Hierro, F., Marcos, M.V., de Zegher, F. “Anovulation in eumenorrheic, nonobese adolescent girls born small for gestational age: insulin sensitization induces ovulation, increases lean body mass, and reduces abdominal fat excess, dyslipidemia, and subclinical hyperandrogenism.” J Clin Endocrinol Metab., 87(2002):5702-5705.
  98. 94. Diamanti-Kandarakis, E., Christakou, C., Palioura, E., Kandaraki, E., Livadas, S. “Does polycystic ovary syndrome start in childhood?” Pediatr Endocrinol Rev., 5(2008):904-911.
  99. 95. Laitinen, J., Taponen, S., Martikainen, H., et al. “Body size from birth to adulthood as a predictor of self-reported polycystic ovary syndrome symptoms.” Int J Obes Relat Metab Disord., 27(2003):710-715.
  100. 96. Ibáñez, L., de Zegher, F., Potau, N. “Anovulation after precocious pubarche: early markers and time course in adolescence.” J Clin Endocrinol Metab., 84(1999):2691-2695.
  101. 97. Azziz, R. “Polycystic ovary syndrome is a family affair.” J Clin Endocrinol Metab., 93(2008):1579-1581.
  102. 98. Recabarren, S.E., Smith, R., Rios, R., et al. “Metabolic profile in sons of women with polycystic ovary syndrome.” J Clin Endocrinol Metab., 93(2008):1820-1826.
  103. 99. Speert, H. “Carcinoma of the endometrium in young women.” Surg Gynecol Obstet., 88(1949):332-336.
  104. 100. Wild, S., Pierpoint, T., Jacobs, H., McKeigue, P. “Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study.” Hum Fertil Camb., 3(2000):101-105.
  105. 101. Chittenden, B.G., Fullerton, G., Maheshwari, A., Bhattacharya, S. “Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review.” Reprod Biomed Online., 19(2009):398-405.
  106. 102. Haoula, Z., Salman, M., Atiomo, W. “Evaluating the association between endometrial cancer and polycystic ovary syndrome.” Hum Reprod., 27(2012):1327-1331.
  107. 103. Dahlgren, E., Friberg, L.G., Johansson, S., et al. «Endometrial carcinoma; ovarian dysfunction–a risk factor in young women.» Eur J Obstet Gynecol Reprod Biol., 41(1991):143-150.
  108. 104. Folsom, A.R., Kaye, S.A., Potter, J.D., Prineas, R.J. “Association of incident carcinoma of the endometrium with body weight and fat distribudoi:10.1210/jc.2013-2350 jcem.endojournals.org 23 tion in older women: early findings of the Iowa Women’s Health Study.” Cancer Res., 49(1989):6828-6831.
  109. 105. McCullough, M.L., Patel, A.V., Patel, R., et al. “Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype.” Cancer Epidemiol Biomarkers Prev., 17(2008):73-79.
  110. 106. O’Mara, B.A., Byers, T., Schoenfeld, E. “Diabetes mellitus and cancer risk: a multisite case-control study.” J Chronic Dis., 38(1985):435-441.
  111. 107. Weiderpass, E., Gridley, G., Persson, I., Nyrén, O., Ekbom, A., Adami, H.O. “Risk of endometrial and breast cancer in patients with diabetes mellitus.” Int J Cancer., 71(1997):360-363.
  112. 108. Friberg, E., Mantzoros, C.S., Wolk, A. “Diabetes and risk of endometrial cancer: a population-based prospective cohort study.” Cancer Epidemiol Biomarkers Prev., 16(2007):276-280.
  113. 109. Koss, L.G., Schreiber, K., Oberlander, S.G., Moussouris, H.F., Lesser, M. “Detection of endometrial carcinoma and hyperplasia in asymptomatic women.” Obstet Gynecol., 64(1984):1-11.
  114. 110. Dreisler, E., Sorensen, S.S., Ibsen, P.H., Lose, G. “Value of endometrial thickness measurement for diagnosing focal intrauterine pathology inwomenwithout abnormal uterine bleeding.” Ultrasound Obstet Gynecol., 33(2009):344-348.
  115. 111. Timmermans, A., Opmeer, B.C., Khan, K.S., et al. “Endometrial thickness measurement for detecting endometrial cancer in women with postmenopausal bleeding: a systematic review and meta-analysis.” Obstet Gynecol., 116(2010):160-167.
  116. 112. Smith, R.A.,von Eschenbach, A.C., Wender, R., et al; AC S Prostate Cancer Advisory Committee, AC S Colorectal Cancer Advisory Committee,AC SEndometrial Cancer Advisory Committee. “American Cancer Society guidelines for the early detection of cancer:update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001–testing for early lung cancer detection.” CA Cancer J Clin., 51(2001):38-75.
  117. 113. Ehrmann, D.A. “Polycystic ovary syndrome.” N Engl J Med., 352(2005):1223-1236.
  118. 114. Yildiz, B.O., Knochenhauer, E.S., Azziz, R. “Impact of obesity on the risk for polycystic ovary syndrome.” J Clin Endocrinol Metab., 93(2008):162-168.
  119. 115. Sam, S., Coviello, A.D., Sung, Y.A., Legro, R.S., Dunaif, A. “Metabolic phenotype in the brothers of women with polycystic ovary syndrome.” Diabetes Care., 31(2008):1237-1241.
  120. 116. Ezeh, U., Yildiz, B.O., Azziz, R. “Referral bias in defining the phenotype and prevalence of obesity in polycystic ovary syndrome.” J Clin Endocrinol Metab., 98(2013):E1088-E1096.
  121. 117. Gambineri, A., Pelusi, C., Vicennati, V., Pagotto, U., Pasquali, R. “Obesity and the polycystic ovary syndrome.” Int J Obes Relat Metab Disord., 26(2002):883-896.
  122. 118. Pasquali, R., Gambineri, A., Pagotto, U. “The impact of obesity on reproduction in women with polycystic ovary syndrome.” BJOG., 113(2006):1148-1159.
  123. 119. Pasquali, R. “Obesity and androgens: facts and perspectives.” Fertil Steril., 85(2006):1319-1340.
  124. 120. Stener-Victorin, E., Holm, G., Labrie, F., Nilsson, L., Janson, P.O., Ohlsson, C. “Are there any sensitive and specific sex steroid markers for polycystic ovary syndrome?” J Clin Endocrinol Metab., 95(2010):810-819.
  125. 121. McCartney, C.R., Prendergast, K.A., Chhabra, S., et al. “The association of obesity and hyperandrogenemia during the pubertal transition in girls: obesity as a potential factor in the genesis of postpubertal hyperandrogenism.” J Clin Endocrinol Metab., 91(2006):1714-1722.
  126. 122. Nyboe Andersen, A., Balen, A., Platteau, P., Devroey, P., Helmgaard, L., Arce, J.C. “Predicting the FSH threshold dose in women with WHO Group II anovulatory infertility failing to ovulate or conceive on clomiphene citrate.” Hum Reprod., 23(2008):1424-1430.
  127. 123. Dunaif, A., Sega, K.R., Futterweit, W., Dobrjansky, A. “Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome.” Diabetes., 38(1989):1165-1174.
  128. 124. Morales, A.J., Laughlin, G.A., Bützow,T., Maheshwari, H., Baumann, G., Yen, S.S. ”Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features.” J Clin Endocrinol Metab., 81(1996):2854-2864.
  129. 125. Legro, R.S., Kunselman, A.R., Dodson, W.C., Dunaif, A. “Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women.” J Clin Endocrinol Metab., 84(1999):165–169.
  130. 126. Ehrmann, D.A., Barnes, R.B., Rosenfield, R.L., Cavaghan, M.K., Imperial, J. “Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.” Diabetes Care., 22(1999):141-146.
  131. 127. Moran, L.J., Misso, M.L., Wild, R.A., Norman, R.J. “Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis.” Hum Reprod Update., 16(2010):347-363.
  132. 128. Ehrmann, D.A., Liljenquist, D.R., Kasza, K., Azziz, R., Legro, R.S., Ghazzi, M.N.; PCO S/ Troglitazone Study Group. “Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome.” J Clin Endocrinol Metab., 91(2006):48-53.
  133. 129. Eriksson, J.G., Forsén, T., Tuomilehto, J., Winter, P.D., Osmond, C., Barker, D.J. “Catch-up growth in childhood and death from coronary heart disease: longitudinal study.” BMJ., 318(1999):427-431.
  134. 130. Diamanti-Kandarakis, E., Christakou, C.D., Kandaraki, E., Alexandraki, K.I. “Early onset adiposity: a pathway to polycystic ovary syndrome in adolescents?” Hormones (Athens)., 6(2007):210-217.
  135. 131. Weiner, C.L., Primeau, M., Ehrmann, D.A. “Androgens and mood dysfunction in women: comparison of women with polycystic ovarian syndrome to healthy controls.” Psychosom Med., 66(2004):356-362.
  136. 132. Bhattacharya, S.M., Jha, A. “Prevalence and risk of depressive disorders in women with polycystic ovary syndrome (PCO S).” Fertil Steril., 94(2010):357-359.
  137. 133. Hollinrake, E., Abreu, A., Maifeld, M., van Voorhis, B.J., Dokras, A. “Increased risk of depressive disorders in women with polycystic ovary syndrome.” Fertil Steril., 87(2007):1369-1376.
  138. 134. Månsson, M., Holte, J., Landin-Wilhelmsen, K., Dahlgren, E., Johansson, A., Landén, M. “Women with polycystic ovary syndrome are often depressed or anxious–a case control study.” Psychoneuroendocrinology., 33(2008):1132-1138.
  139. 135. Kerchner, A., Lester, W., Stuart, S.P., Dokras, A. “Risk of depression and other mental health disorders in women with polycystic ovary syndrome: a longitudinal study.” Fertil Steril., 91(2009):207-212.
  140. 136. Stunkard, A.J., Faith, M.S., Allison, K.C. “Depression and obesity.” Biol Psychiatry., 54(2003):330-337.
  141. 137. Jedel, E., Waern, M., Gustafson, D., et al. “Anxiety and depression symptoms in women with polycystic ovary syndrome compared with controls matched for body mass index.” Hum Reprod., 25(2010):450-456.
  142. 138. Dokras, A., Clifton, S., Futterweit, W., Wild, R. “Increased risk for abnormal depression scores in women with polycystic ovary syndrome: a systematic review and meta-analysis.” Obstet Gynecol., 117(2011):145-152.
  143. 139. Dokras, A., Clifton, S., Futterweit, W.,Wild, R. “Increased prevalence of anxiety symptoms in women with polycystic ovary syndrome: systematic review and meta-analysis.” Fertil Steril., 97(2012):225-230.e2.
  144. 140. Gilbody, S., Richards, D., Brealey, S., Hewitt, C. “Screening for depression in medical settings with the Patient Health Questionnaire (PHQ): a diagnostic meta-analysis.” J Gen Intern Med., 22(2007):1596-1602.
  145. 141. Vgontzas, A.N., Legro, R.S., Bixler, E.O., Grayev, A., Kales, A., Chrousos, G.P. “Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance.” J Clin Endocrinol Metab., 86(2001):517-520.
  146. 142. Gopal, M., Duntley, S., Uhles, M., Attarian, H. “The role of obesity in the increased prevalence of obstructive sleep apnea syndrome in 24 Legro et al Guidelines on PCO S J Clin Endocrinol Metab patients with polycystic ovarian syndrome.” Sleep Medicine., 3(2002):401-404.
  147. 143. Shahar, E., Redline, S., Young, T., et al. “Hormone replacement therapy and sleep-disordered breathing.” AmJ Respir Crit Care Med., 167(2003):1186-1192.
  148. 144. Tasali, E., Chapotot, F., Leproult, R., Whitmore, H., Ehrmann, D.A. “Treatment of obstructive sleep apnea improves cardiometabolic function in young obese women with polycystic ovary syndrome.” J Clin Endocrinol Metab., 96(2011):365-374.
  149. 145. Ratziu, V., Bellentani, S., Cortez-Pinto, H., Day, C., Marchesini, G. “A position statement on NAFLD/NASH based on the EASL 2009 special conference.” J Hepatol., 53(2010):372-384.
  150. 146. Baumeister, S.E., Völzke, H., Marschall, P., et al. “Impact of fatty liver disease on health care utilization and costs in a general population: a 5-year observation.” Gastroenterology., 134(2008):85-94.
  151. 147. Setji, T.L., Holland, N.D., Sanders, L.L., Pereira, K.C., Diehl, A.M., Brown, A.J. “Nonalcoholic steatohepatitis and nonalcoholic fatty liver disease in young women with polycystic ovary syndrome.” J Clin Endocrinol Metab., 91(2006):1741-1747.
  152. 148. Loria, P., Carulli, L., Bertolotti, M., Lonardo, A. “Endocrine and liver interaction: the role of endocrine pathways in NASH.” Nat Rev Gastroenterol Hepatol., 6(2009):236-247.
  153. 149. Gambarin-Gelwan, M., Kinkhabwala, S.V., Schiano, T.D., Bodian, C., Yeh, H.C., Futterweit, W. “Prevalence of nonalcoholic fatty liver disease inwomenwith polycystic ovary syndrome.” Clin Gastroenterol Hepatol., 5(2007):496-501.
  154. 150. Cerda, C., Pérez-Ayuso, R.M., Riquelme, A., et al. “Nonalcoholic fatty liver disease in women with polycystic ovary syndrome.” J Hepatol., 47(2007):412-417.
  155. 151. Schwimmer, J.B., Khorram, O., Chiu, V., Schwimmer, W.B. “Abnormal aminotransferase activity in women with polycystic ovary syndrome.” Fertil Steril., 83(2005):494-497.
  156. 152. Gutierrez-Grobe, Y., Ponciano-Rodríguez, G., Ramos, M.H., Uribe, M., Méndez-Sánchez, N. “Prevalence of non alcoholic fatty liver disease in premenopausal, postmenopausal and polycystic ovary syndrome women.” The role of estrogens.» Ann Hepatol., 9(2010):402-409.
  157. 153. Vassilatou, E., Lafoyianni, S., Vryonidou, A., et al. “Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome.” Hum Reprod., 25(2010):212-220.
  158. 154. Mojiminiyi, O.A., Safar, F.H., Al Rumaih, H., Diejomaoh, M. “Variations in alanine aminotransferase levels within the normal range predict metabolic and androgenic phenotypes in women of reproductive age.” Scand J Clin Lab Invest., 70(2010):554-560.
  159. 155. Kauffman, R.P., Baker, T.E., Baker, V., Kauffman, M.M., Castracane, V.D. “Endocrine factors associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome: do androgens play a role?” Gynecol Endocrinol., 26(2010):39-46.
  160. 156. de Lédinghen,V., Ratziu, V., Causse, X., et al; Association Francaise pour l’Etude du Foie Groupe Epidemiologie et Evaluation: Association Nationale des Gastroenterologues des Hopitaux generaux de France. “Diagnostic and predictive factors of significant liver fibrosis and minimal lesions in patients with persistent unexplained elevated transaminases. A prospective multicenter study.” J Hepatol., 45(2006):592-599.
  161. 157. Palmert, M.R., Gordon, C.M., Kartashov, A.I., Legro, R.S., Emans, S.J., Dunaif, A. “Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome.” J Clin Endocrinol Metab., 87(2002):1017-1023.
  162. 158. Legro, R.S., Gnatuk, C.L., Kunselman, A.R., Dunaif, A. “Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study.” J Clin Endocrinol Metab., 90(2005):3236-3242.
  163. 159. Velling Magnussen, L., Mumm, H., Andersen, M., Glintborg, D. “Hemoglobin A1c as a tool for the diagnosis of type 2 diabetes in 208 premenopausal women with polycystic ovary syndrome.” Fertil Steril., 96(2011):1275-1280.
  164. 160. Norman, R.J., Masters, L., Milner, C.R., Wang, J.X., Davies, M.J. “Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome.” Hum Reprod., 16(2001):1995-1998.
  165. 161. Alberti, K.G., Zimmet, P., Shaw, J. “International Diabetes Federation: a consensus on type 2 diabetes prevention.” Diabet Med., 24(2007):451-463.
  166. 162. American Association of Clinical Endocrinologists Polycystic Ovary Syndrome Writing Committee. “American Association of Clinical Endocrinologists position statement on metabolic and cardiovascular consequences of polycystic ovary syndrome.” Endocr Pract., 11(2005):126-134.
  167. 163. Salley, K.E., Wickham, E.P., Cheang, K.I., Essah, P.A., Karjane, N.W., Nestler, J.E. “Glucose intolerance in polycystic ovary syndrome–a position statement of the Androgen Excess Society.” J Clin Endocrinol Metab., 92(2007):4546-4556.
  168. 164. Lundblad, D., Eliasson, M. “Silent myocardial infarction in women with impaired glucose tolerance: the Northern Sweden MONICA study.” Cardiovasc Diabetol., 2(2003):9.
  169. 165. Brohall, G., Schmidt, C., Behre, C.J., Hulthe, J., Wikstrand, J., Fagerberg, B. “Association between impaired glucose tolerance and carotid atherosclerosis: a study in 64-yearold women and a meta-analysis.”Nutr Metab Cardiovasc Dis., 19(2009):327-333.
  170. 166. Dmitrovic, R., Katcher, H.I., Kunselman, A.R., Legro, R.S. “Continuous glucose monitoring during pregnancy in women with polycystic ovary syndrome.” Obstet Gynecol., 118(2011):878-885.
  171. 167. Wild, R.A., Carmina, E., Diamanti-Kandarakis, E., et al. “Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AEPCO S) Society.” J Clin Endocrinol Metab., 95(2010):2038-2049.
  172. 168. Zimmermann, S., Phillips, R.A., Dunaif, A., et al. “Polycystic ovary syndrome: lack of hypertension despite profound insulin resistance.” J Clin Endocrinol Metab., 75(1992):508-513.
  173. 169. Dahlgren, E., Janson, P.O., Johansson, S., Lapidus, L., Odén, A. “Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women.” Acta Obstet Gynecol Scand., 71(1992):599-604.
  174. 170. Dahlgren, E., Johansson, S., Lindstedt, G., et al. “Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones.” Fertil Steril., 57(1992):505-513.
  175. 171. Wild, R.A., Vesely, S., Beebe, L., Whitsett, T., Owen, W. “Ferriman Gallwey self-scoring I: performance assessment in women with polycystic ovary syndrome.” J Clin Endocrinol Metab., 90(2005):4112-4114.
  176. 172. Holte, J., Gennarelli, G., Berne, C., Bergh, T., Lithell, H. “Elevated ambulatory day-time blood pressure in women with polycystic ovary syndrome: a sign of a pre-hypertensive state?” Hum Reprod., 11(1996):23-28.
  177. 173. Arslanian, S.A., Lewy, V.D., Danadian, K. “Glucose intolerance in obese adolescents with polycystic ovary syndrome: roles of insulin resistance and - cell dysfunction and risk of cardiovascular disease.” J Clin Endocrinol Metab., 86(2001):66-71.
  178. 174. Talbott, E.O., Zborowski, J.V., Boudreaux, M.Y., McHugh-Pemu, K.P., Sutton-Tyrrell, K., Guzick, D.S. “The relationship between C-reactive protein and carotid intima-media wall thickness in middleaged women with polycystic ovary syndrome.” J Clin Endocrinol Metab., 89(2004):6061-6067.
  179. 175. Talbott, E.O., Zborowski, J.V., Rager, J.R., Boudreaux, M.Y., Edmundowicz, D.A., Guzick, D.S. “Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome.” J Clin Endocrinol Metab., 89(2004):5454-5461.
  180. 176. Christian, R.C., Dumesic, D.A., Behrenbeck, T., Oberg, A.L., Sheedy, P.F., 2nd, Fitzpatrick, L.A. “Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome.” J Clin Endocrinol Metab., 88(2003):2562-2568. doi: 10.1210/jc.2013-2350 jcem. endojournals.org 25
  181. 177. Shroff, R., Kerchner, A., Maifeld, M., van Beek, E.J., Jagasia, D., Dokras, A. “Young obese women with polycystic ovary syndrome have evidence of early coronary atherosclerosis.” J Clin Endocrinol Metab., 92(2007):4609-4614.
  182. 178. Orio, F.Jr., Palomba, S., Spinelli, L., et al. “The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study.” J Clin Endocrinol Metab., 89(2004):3696-3701.
  183. 179. Yarali, H., Yildirir, A., Aybar, F., et al. “Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome.” Fertil Steril., 76(2001):511-516.
  184. 180. Tíras, M.B., Yalcìn, R., Noyan, V., et al. “Alterations in cardiac flow parameters in patients with polycystic ovarian syndrome.” Hum Reprod., 14(1999):1949-1952.
  185. 181. Ketel, I.J., Stehouwer, C.D., Henry, R.M., et al. “Greater arterial stiffness in polycystic ovary syndrome (PCO S) is an obesity–but not a PCO Sassociated phenomenon.” J Clin Endocrinol Metab., 95(2010):4566-4575.
  186. 182. Beckman, J.A., Goldfine, A.B., Dunaif, A., Gerhard-Herman, M., Creager, M.A. “Endothelial function varies according to insulin resistance disease type.” Diabetes Care., 30(2007):1226-1232.
  187. 183. Bickerton, A.S., Clark, N., Meeking, D., et al. “Cardiovascular risk in women with polycystic ovarian syndrome (PCO S).” J Clin Pathol., 58(2005):151-154.
  188. 184. Meyer, C., McGrath, B.P., Teede, H.J. “Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease.” J Clin Endocrinol Metab., 90(2005):5711-5716.
  189. 185. Carmina, E., Orio, F., Palomba, S., et al. “Endothelial dysfunction in PCO S: role of obesity and adipose hormones.” Am J Med., 119(2006):356.e1;e6.186.
  190. 186. Kravariti, M., Naka, K.K., Kalantaridou, S.N., et al. “Predictors of endothelial dysfunction in young women with polycystic ovary syndrome.” J Clin Endocrinol Metab., 90(2005):5088-5095.
  191. 187. Orio, F.Jr., Palomba, S., Cascella, T., et al. “Improvement in endothelial structure and function after metformin treatment in young normalweight women with polycystic ovary syndrome: results of a 6-month study.” J Clin Endocrinol Metab., 90(2005):6072-6076.
  192. 188. Tarkun, I., Cetinarslan, B., Türemen, E., Sahin, T., Cantürk, Z., Komsuoglu, B. “Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in nonobese young women with polycystic ovary syndrome.” Eur J Endocrinol., 153(2005):115-121.
  193. 189. Diamanti-Kandarakis, E., Spina, G., Kouli, C., Migdalis, I. “Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy.” JCEM., 86(2001):4666-4673.
  194. 190. Diamanti-Kandarakis, E., Alexandraki, K., Protogerou, A., et al. “Metformin administration improves endothelial function in women with polycystic ovary syndrome.” Eur J Endocrinol., 152(2005):749-756.
  195. 191. Schmidt, J., Landin-Wilhelmsen, K., Brännström, M., Dahlgren, E. “Cardiovascular disease and risk factors in PCO S women of postmenopausal age: a 21-year controlled follow-up study.” J Clin Endocrinol Metab., 96(2011):3794-3803.
  196. 192. Solomon, C.G., Hu, F.B., Dunaif, A., et al. “Menstrual cycle irregularity and risk for future cardiovascular disease.” J Clin Endocrinol Metab., 87(2002):2013-2017.
  197. 193. Rexrode, K.M., Manson, J.E., Lee, I.M., et al. “Sex hormone levels and risk of cardiovascular events in postmenopausal women.” Circulation., 108(2003):1688-1693.
  198. 194. Shaw, L.J., Bairey Merz, C.N., Azziz, R., et al. “Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health–National Heart, Lung, and Blood Institute sponsored Women’s Ischemia Syndrome Evaluation.” J Clin Endocrinol Metab., 93(2008):1276-1284.
  199. 195. Vrbíková, J., Cibula, D. “Combined oral contraceptives in the treatment of polycystic ovary syndrome.” Hum Reprod Update., 11(2005);277-291.
  200. 196. Legro, R.S., Pauli, J.G., Kunselman, A.R., et al. “Effects of continuous versus cyclical oral contraception: a randomized controlled trial.” J Clin Endocrinol Metab., 93(2008):420-429.
  201. 197. Watanabe, R.M., Azen, C.G., Roy, S., Perlman, J.A., Bergman, R.N. “Defects in carbohydrate metabolism in oral contraceptive users without apparent metabolic risk factors.” J Clin Endocrinol Metab., 79(1994):1277-1283.
  202. 198. Cagnacci, A., Ferrari, S., Tirelli, A., Zanin, R., Volpe, A. “Insulin sensitivity and lipid metabolism with oral contraceptives containing chlormadinone acetate or desogestrel: a randomized trial.” Contraception., 79(2009):111-116.
  203. 199. Van der Vange, N., Kloosterboer, H.J., Haspels, A.A. “Effect of seven low-dose combined oral contraceptive preparations on carbohydrate metabolism.” Am J Obstet Gynecol., 156(1987):918-922.
  204. 200. Simon, D., Senan, C., Garnier, P., et al. “Effects of oral contraceptives on carbohydrate and lipid metabolisms in a healthy population: the Telecom study.” Am J Obstet Gynecol., 163(1990):382-387.
  205. 201. Godsland, I.F., Crook, D., Worthington, M., et al. “Effects of a lowestrogen, desogestrel-containing oral contraceptive on lipid and carbohydrate metabolism.” Contraception., 48(1993):217-227.
  206. 202. Crook, D., Godsland, I.F., Worthington, M., Felton, C.V., Proudler, A.J., Stevenson, J.C. “Acomparative metabolic study of two low-estrogendose oral contraceptives containing desogestrel or gestodene progestins.”Am J Obstet Gynecol., 169(1993):1183-1189.
  207. 203. Lopez, L.M., Grimes, D.A., Schulz, K.F. “Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus.” Cochrane Database Syst Rev., 4(2009):CD006133.
  208. 204. Rimm, E.B., Manson, J.E., Stampfer, M.J., et al. “Oral contraceptive use and the risk of type 2 (non-insulin-dependent) diabetes mellitus in a large prospective study of women.» Diabetologia., 35(1992):967-972.
  209. 205. Skouby, S.O., Endrikat, J., Düsterberg, B., et al. «A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 microg ethinyl estradiol combined with 100 microg levonorgestrel.” Contraception., 71(2005):111-117.
  210. 206. Kjos, S.L., Peters, R.K., Xiang, A., Thomas, D., Schaefer, U., Buchanan, T.A. “Contraception and the risk of type 2 diabetes mellitus in Latina women with prior gestational diabetes mellitus.” JAMA ., 280(1998):533-538.
  211. 207. Garg, S.K., Chase, H.P., Marshall, G., Hoops, S.L., Holmes, D.L., Jackson, W.E. “Oral contraceptives and renal and retinal complications in young women with insulin-dependent diabetes mellitus.” JAMA ., 271(1994):1099-1102.
  212. 208. Morin-Papunen, L., Vauhkonen, I., Koivunen, R., Ruokonen, A., Martikainen, H., Tapanainen, J.S. “Metformin versus ethinyl estradiolcyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study.” J Clin Endocrinol Metab., 88(2003):148-156.
  213. 209. Elter, K., Imir, G., Durmusoglu, F. “Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone
  214. acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study.” Hum Reprod., 17(2002):1729-1737.
  215. 210. Cagnacci, A., Paoletti, A.M., Renzi, A., et al. “Glucose metabolism and insulin resistance inwomenwith polycystic ovary syndrome during therapy with oral contraceptives containing cyproterone acetate or desogestrel.” J Clin Endocrinol Metab., 88(2003):3621-3625.
  216. 211. Domecq, J.P., Prutsky, G., Mullan, R., et al. “Lifestyle modification programs in polycystic ovary syndrome: systematic review and metaanalysis [published online ahead of print October 3, 2013].” J Clin Endocrinol Metab., doi:10.1210/ jc.2013-2385.
  217. 212. American Diabetes Association. “Preconception care of women with diabetes.” Diabetes Care., 26(Suppl 1) (2003):S91-S93.
  218. 213. Frempong, B.A., Ricks, M., Sen, S., Sumner, A.E. “Effect of low-dose oral contraceptives on metabolic risk factors in African-American women.” J Clin Endocrinol Metab., 93(2008):2097-2103.26 Legro et al Guidelines on PCO S J Clin Endocrinol Metab.
  219. 214. Winkler, U.H., Sudik, R. “The effects of two monophasic oral contraceptives containing 30 mcg of ethinyl estradiol and either 2 mg of chlormadinone acetate or 0.15 mg of desogestrel on lipid, hormone and metabolic parameters.” Contraception., 79(2009):15-23.
  220. 215. Gaspard, U., Endrikat, J., Desager, J.P., Buicu, C., Gerlinger, C., Heithecker, R. “A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles.” Contraception., 69(2004):271-278.
  221. 216. Akerlund, M., Almström, E., Högstedt, S., Nabrink, M. “Oral contraceptive tablets containing 20 and 30 micrograms of ethinyl estradiol with 150 micrograms desogestrel.” Their influence on lipids, lipoproteins, sex hormone binding globulin and testosterone.” Acta Obstet Gynecol Scand., 73(1994):136-143.
  222. 217. Gevers Leuven, J.A., Dersjant-Roorda, M.C., Helmerhorst, F.M., de Boer, R., Neymeyer-Leloux, A., Havekes, L. “Estrogenic effect of gestodene-or desogestrel-containing oral contraceptives on lipoprotein metabolism.” Am J Obstet Gynecol., 163(1990):358-362.
  223. 218. Van der Mooren, M.J., Klipping, C., van Aken, B., Helmerhorst, E., Spielmann, D., Kluft, C. “A comparative study of the effects of gestodene 60 microg/ethinylestradiol 15 microg and desogestrel 150 microg/ethinylestradiol 20 microg on hemostatic balance, blood lipid levels and carbohydrate metabolism.” Eur J Contracept Reprod Health Care., 4(1999):27-35.
  224. 219. Porcile, A., Gallardo, E. “Long-term treatment of hirsutism: desogestrel compared with cyproterone acetate in oral contraceptives.” Fertil Steril., 55(1991):877-881.
  225. 220. Ibáñez, L., de Zegher, F.
  226. “Ethinylestradiol-drospirenone, flutamidemetformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity.” J Clin Endocrinol Metab., 89(2004):1592-1597.
  227. 221. Mastorakos, G., Koliopoulos, C., Creatsas, G. “Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives.” Fertil Steril., 77(2002):919-927.
  228. 222. Rautio, K., Tapanainen, J.S., Ruokonen, A., Morin-Papunen, L.C. “Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and nonobese women with polycystic ovary syndrome.” Eur J Endocrinol., 152(2005):269-275.
  229. 223. Hoeger, K., Davidson, K., Kochman, L., Cherry, T., Kopin, L., Guzick, D.S. “The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials.” J Clin Endocrinol Metab., 93(2008):4299-4306.
  230. 224. Goldzieher, J.W., Moses, L.E., Averkin, E., Scheel, C., Taber, B.Z. “A placebo-controlled double-blind crossover investigation of the side effects attributed to oral contraceptives.” Fertil Steril., 22(1971):609-623.
  231. 225. Coney, P., Washenik, K., Langley, R.G., DiGiovanna, J.J., Harrison, D.D. “Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials.” Contraception., 63(2001):297-302.
  232. 226. Gallo, M.F., Lopez, L.M., Grimes, D.A., Schulz, K.F., Helmerhorst, F.M. “Combination contraceptives: effects on weight.” Cochrane Database Syst Rev., 4(2008):CD003987.
  233. 227. Pasquali, R., Gambineri, A., Anconetani, B., et al. “The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment.” Clin Endocrinol (Oxf).,
  234. (1999):517-527.
  235. 228. World Health Organization. “Medical eligibility criteria for contraceptive use.” 4th ed. Accessible at http://whqlibdoc.who.int/ publications/2010/9789241563888_eng.pdf. 2009.
  236. 229. Blair, S.N., Kohl, H.W., 3rd, Paffenbarger, R.S. Jr., Clark, D.G., Cooper, K.H., Gibbons, L.W. “Physical fitness and all-cause mortality. A prospective study of healthy men and women.” JAMA ., 262(1989):2395-2401.
  237. 230. Knowler, W., Barrett-Connor, E., Fowler, S.E., et al; Diabetes Prevention Program Research Group. “Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.” N Engl J Med., 346(2002):393-403.
  238. 231. Hu, G., Lakka, T.A., Kilpeläinen, T.O., Tuomilehto, J. “Epidemiological studies of exercise in diabetes prevention.” Appl Physiol Nutr Metab., 32(2007):583-595.
  239. 232. Lakka, T.A., Laaksonen, D.E. “Physical activity in prevention and treatment of the metabolic syndrome.” Appl Physiol Nutr Metab., 32(2007):76-88.
  240. 233. Harrison, C.L., Lombard, C.B., Moran, L.J., Teede, H.J. “Exercise therapy in polycystic ovary syndrome: a systematic review.” Hum Reprod Update., 17(2011):171-183.
  241. 234. Orio, F. Jr., Giallauria, F., Palomba, S., et al. “Cardiopulmonary impairment in young women with polycystic ovary syndrome.” J Clin Endocrinol Metab., 91(2006):2967-2971.
  242. 235. Thomson, R.L., Buckley, J.D., Moran, L.J., et al. “Comparison of aerobic exercise capacity and muscle strength in overweight women with and without polycystic ovary syndrome.” BJOG., 116(2009):1242-1250.
  243. 236. Stener-Victorin, E., Jedel, E., Janson, P.O., Sverrisdottir, Y.B. “Low-frequency electroacupuncture and physical exercise decrease high muscle sympathetic nerve activity in polycystic ovary syndrome.”Am J Physiol Regul Integr Comp Physiol., 297(2009):R387-R395.
  244. 237. Moro, C., Pasarica, M., Elkind-Hirsch, K., Redman, L.M. “Aerobic exercise training improves atrial natriuretic peptide and catecholamine-mediated lipolysis in obese women with polycystic ovary syndrome.” J Clin Endocrinol Metab., 94(2009):2579-2586.
  245. 238. Palomba, S., Falbo, A., Orio, F. Jr., Zullo, F. “Effect of preconceptional metformin on abortion risk in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials.” Fertil Steril., 92(2009):1646-1658.
  246. 239. Thomson, R.L., Buckley, J.D., Noakes, M., Clifton, P.M., Norman, R.J., Brinkworth, G.D. “The effect of a hypocaloric diet with and without exercise training on body composition, cardiometabolic risk profile, and reproductive function in overweight and obese women with polycystic ovary syndrome.” J Clin Endocrinol Metab., 93(2008):3373-3380.
  247. 240. Florakis, D., Diamanti-Kandarakis, E., Katsikis, I., et al. “Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study.” Int J Obes (Lond)., 32(2008):692-699.
  248. 241. Escobar-Morreale, H.F., Botella-Carretero, J.I., Alvarez-Blasco, F., Sancho, J., San Millán, J.L. “The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery.” J Clin Endocrinol Metab., 90(2005):6364-6369.
  249. 242. Pasquali, R., Gambineri, A., Cavazza, C., et al. “Heterogeneity in the responsiveness to long-term lifestyle intervention and predictability in obese women with polycystic ovary syndrome.” Eur J Endocrinol., 164(2011):53-60.
  250. 243. Kiddy, D.S., Hamilton-Fairley, D., Bush, A., et al. “Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome.” Clin Endocrinol (Oxf), 36(1992):105-111.
  251. 244. Moran, L.J., Noakes, M., Clifton, P.M., Tomlinson, L., Galletly, C., Norman, R.J. “Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome.” J Clin Endocrinol Metab., 88(2003):812-819.
  252. 245. Clark, A.M., Thornley, B., Tomlinson, L., Galletley, C., Norman, R.J. “Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment.” Hum Reprod., 13(1998):1502-1505.
  253. 246. Crosignani, P.G., Colombo, M., Vegetti, W., Somigliana, E., Gessati, A., Ragni, G. “Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet.” Hum Reprod., 18(2003):1928-1932.
  254. 247. Huber-Buchholz, M.M., Carey, D.G., Norman, R.J. “Restoration of reproductive potential by lifestyle modification in obese polycystic doi: 10.1210/jc.2013-2350 jcem.endojournals.org 27ovary syndrome: role of insulin sensitivity and luteinizing hormone.” J Clin Endocrinol Metab., 84(1999):1470-1474.
  255. 248. Tang, T., Glanville, J., Hayden, C.J., White, D., Barth, J.H., Balen, A.H. “Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome.» A randomized, placebo-controlled, double-blind multicentre study.” Hum Reprod., 21(2006):80-89.
  256. 249. Tang, T., Glanville, J., Orsi, N., Barth, J.H., Balen, A.H. “The use of metformin forwomenwithPCO Sundergoing IVF treatment.” Hum Reprod., 21(2006):1416-1425.
  257. 250. Domecq, J.P., Prutsky, G., Mullan, R., et al. “Adverse effects of common treatments for polycystic ovary syndrome: a systematic review and meta-analysis [published online ahead of print October 3, 2013].” J Clin Endocrinol Metab., doi:10.1210/jc.2013-2374.
  258. 251. Moran, L.J., Hutchison, S.K., Norman, R.J., Teede, H.J. “Lifestyle changes in women with polycystic ovary syndrome.” Cochrane Database Syst Rev., 7(2011):CD007506.
  259. 252. Teede, H.J., Misso, M.L., Deeks, A.A. “Assessment and management of polycystic ovary syndrome: summary of an evidence-based guideline.” Med J Australia., 195(2011):S65-S112.
  260. 253. Harborne, L., Fleming, R., Lyall, H., Sattar, N., Norman, J. “Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome.” J Clin Endocrinol Metab., 88(2003):4116-4123.
  261. 254. Tang, T., Lord, J.M., Norman, R.J., Yasmin, E., Balen, A.H. “Insulinsensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiroinositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.” Cochrane Database Syst Rev., 1(2010):CD003053.
  262. 255. Nieuwenhuis-Ruifrok, A.E., Kuchenbecker,W.K., Hoek, A., Middleton, P., Norman, R.J. “Insulin sensitizing drugs for weight loss in women of reproductive agewhoare overweight or obese: systematic review and meta-analysis.” Hum Reprod Update., 15(2009):57-68.
  263. 256. Padwal, R., Li, S.K., Lau, D.C. “Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials.” Int J Obes Relat Metab Disord., 27(2003):1437-1446.
  264. 257. Ladson, G., Dodson, W.C., Sweet, S.D., et al. “The effects of metformin with lifestyle therapy in polycystic ovary syndrome: a randomized double-blind study.” Fertil Steril., 95(2011):1059-1066.e1;e7.
  265. 258. Nestler, J.E., Jakubowicz, D.J., Evans, W.S., Pasquali, R. “Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome.” N Engl J Med., 338(1998):1876-1880.
  266. 259. Morin-Papunen, L.C., Vauhkonen, I., Koivunen, R.M., Ruokonen, A., Martikainen, H.K., Tapanainen, J.S. “Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.” J Clin Endocrinol Metab., 85(2000):3161-3168.
  267. 260. Perreault, L., Kahn, S.E., Christophi, C.A., Knowler, W.C., Hamman, R.F. “Regression from pre-diabetes to normal glucose regulation in the diabetes prevention program.” Diabetes Care., 32(2009):1583-1588.
  268. 261. Costello, M., Shrestha, B., Eden, J., Sjoblom, P., Johnson, N. “Insulinsensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome.” Cochrane Database Syst Rev., 1(2007):CD005552.
  269. 262. Palomba, S., Orio, F. Jr., Falbo, A., et al. “Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.” J Clin Endocrinol Metab., 90(2005):4068-4074.
  270. 263. Moll, E., Bossuyt, P.M., Korevaar, J.C., Lambalk, C.B., van der Veen, F. “Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial.” BMJ., 332(2006):1485.
  271. 264. Zain, M.M., Jamaluddin, R., Ibrahim, A., Norman, R.J. “Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial.” Fertil Steril., 91(2009):514-521.
  272. 265. Johnson, N.P., Stewart, A.W., Falkiner, J., et al. “PCO SMIC: a multicenter randomized trial in women with polycystic ovary syndrome evaluating metformin for infertility with clomiphene.” Hum Reprod., 25(2010):1675-1683.
  273. 266. Homburg, R., Hendriks, M.L., König, T.E., et al. “Clomifene citrate or low-dose FSH for the first-line treatment of infertile women with anovulation associated with polycystic ovary syndrome: a prospective randomized multinational study.” Hum Reprod., 27(2012):468-473.
  274. 267. Misso, M.L., Wong, J.L., Teede, H.J., et al. “Aromatase inhibitors for PCO S: a systematic review and meta-analysis.” Hum Reprod Update., 18(2012):301-312.
  275. 268. NIH/NICHD. “Effect of letrozole versus clomiphene on live birth in women with anovulatory infertility due to polycystic ovary syndrome (PCO S): a randomized double-blind multicenter trial.” Fertil Steril., 100(3 suppl) (2013):S51.
  276. 269. Tulandi, T., Martin, J., Al-Fadhli, R., et al. “Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate.” Fertil Steril., 85(2006):1761-1765.
  277. 270. Morin-Papunen, L., Rantala, A.S., Unkila-Kallio, L., et al. “Metformin improves pregnancy and live-birth rates in women with polycystic ovary syndrome (PCO S): a multicenter, double-blind, placebocontrolled randomized trial.” J Clin Endocrinol Metab., 97(2012):1492-1500.
  278. 271. Moll., E. van der Veen, F., van Wely, M. “The role of metformin in polycystic ovary syndrome: a systematic review.” Hum Reprod Update., 13(2007):527-537.
  279. 272. Tso, L.O., Costello, M.F., Albuquerque, L.E., Andriolo, R.B., Freitas, V. “Metformin treatment before and during IVF or ICSI inwomenwith polycystic ovary syndrome.” Cochrane Database Syst Rev., 2(2009):CD006105.
  280. 273. Rowan, J.A., Hague, W.M., Gao, W., Battin, M.R., Moore, M.P. “Metformin versus insulin for the treatment of gestational diabetes.” N Engl J Med., 358(2008):2003-2015.
  281. 274. Vanky, E., Stridsklev, S., Heimstad, R., et al. “Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study.” J Clin Endocrinol Metab., 95(2010):E448-E455.
  282. 275. Galazis, N., Galazi, M., Atiomo, W. “D-Chiro-inositol and its significance in polycystic ovary syndrome: a systematic review.” Gynecol Endocrinol., 27(2011):256-262.
  283. 276. Banaszewska, B., Pawelczyk, L., Spaczynski, R.Z., Duleba, A.J. “Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial.” J Clin Endocrinol Metab., 94(2009):4938-4945.
  284. 277. Izquierdo, D., Foyouzi, N., Kwintkiewicz, J., Duleba, A.J. “Mevastatin inhibits ovarian theca-interstitial cell proliferation and steroidogenesis.” Fertil Steril., 82(Suppl 3) (2004):1193-1197.
  285. 278. Sokalska, A., Piotrowski, P.C., Rzepczynska, I.J., Cress, A., Duleba, A.J. “Statins inhibit growth ofhumantheca-interstitial cells inPCO Sand non-PCO S tissues independently of cholesterol availability.” J Clin Endocrinol Metab., 95(2010):5390-5394.
  286. 279. Sathyapalan, T., Kilpatrick, E.S., Coady, A.M., Atkin, S.L. “The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study.” J Clin Endocrinol Metab., 94(2009):103-108.
  287. 280. Raja-Khan, N., Kunselman, A.R., Hogeman, C.S., Stetter, C.M., Demers, L.M., Legro, R.S. “Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial.” Fertil Steril., 95(2011):1849-1852.
  288. 281. Raval, A.D., Hunter, T., Stuckey, B., Hart, R.J. “Statins for women with polycystic ovary syndrome not actively trying to conceive.” Cochrane Database Syst Rev., 10(2011):CD008565.28 Legro et al Guidelines on PCO S J Clin Endocrinol Metab
  289. 282. Preiss, D., Seshasai, S.R., Welsh, P., et al. “Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.” JAMA , 305(2011):2556-2564.
  290. 283. Guttmann-Bauman, I. “Approach to adolescent polycystic ovary syndrome (PCO S) in the pediatric endocrine community in the U.S.A.” J Pediatr Endocrinol Metab., 18(2005):499-506.
  291. 284. Hillard, P.J. “Oral contraceptives and the management of hyperandrogenism-polycystic ovary syndrome in adolescents.» Endocrinol Metab Clin North Am., 34(2005):707-723, x.
  292. 285. Cedars, M.I. «Polycystic ovary syndrome: what is it and how should we treat it?” J Pediatr., 144(2004):4-6.
  293. 286. Tanner, J.M. “Growth and endocrinology of the adolescent.” In: Gardner L.I., ed. Endocrine and Genetic Diseases of Childhood and Adolescents. 2nd ed. Philadelphia, PA : WB Saunders (1975): 14.
  294. 287. Pfeifer, S.M., Dayal, M. “Treatment of the adolescent patient with polycystic ovary syndrome.” Obstet Gynecol Clin NorthAm., 30(2003):337-352.
  295. 288. Buggs, C., Rosenfield, R.L. “Polycystic ovary syndrome in adolescence.” Endocrinol Metab Clin North Am., 34(2005):677-705, x.
  296. 289. Ibáñez, L., Valls, C., Ferrer, A., Marcos, M.V., Rodriguez-Hierro, F., de Zegher, F. “Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism.” J Clin Endocrinol Metab., 86(2001):3595-3598.
  297. 290. Ibáñez, L., Valls, C., Potau, N., Marcos, M.V., de Zegher, F. “Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche.” J Clin Endocrinol Metab., 85(2000):3526-3530.
  298. 291. Arslanian, S.A., Lewy, V., Danadian, K., Saad, R. “Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance.” J Clin Endocrinol Metab., 87(2002):1555-1559.
  299. 292. Harwood, K., Vuguin, P., DiMartino-Nardi, J. “Current approaches to the diagnosis and treatment of polycystic ovarian syndrome in youth.” Horm Res., 68(2007):209-217.
  300. 293. Ladson, G., Dodson, W.C., Sweet, S.D., et al. “Effects of metformin in adolescents with polycystic ovary syndrome undertaking lifestyle therapy: a pilot randomized double-blind study.” Fertil Steril., 95(2011):2595-2598.e1;e6.
  301. 294. De Leo, V., Musacchio, M.C., Morgante, G., Piomboni, P., Petraglia, F. “Metformin treatment is effective in obese teenage girls with PCO S.” Hum Reprod., 21(2006):2252-2256.
  302. 295. Rosenfield, R.L. “Clinical practice. Hirsutism.” N Engl J Med., 353(2005):2578-2588.
  303. 296. Nelson, L.M. “Clinical practice. Primary ovarian insufficiency.” N Engl J Med., 360(2009):606-614.

Downloads

Published

2014-12-19

How to Cite

Legro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., Pasquali, R., & Welt, C. K. (2014). Diagnosis and treatment of polycystic ovary syndrome: an endocrine society clinical practice guideline. REPRODUCTIVE ENDOCRINOLOGY, (20), 22–35. https://doi.org/10.18370/2309-4117.2014.20.22-35

Issue

No. 20 (2014)

Section

Clinical guidelines

License

Copyright (c) 2015 Richard S. Legro, Silva A. Arslanian, David A. Ehrmann, Kathleen M. Hoeger, M. Hassan Murad, Renato Pasquali, Corrine K. Welt

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.